Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
EG 427 Logo
EG 427 Growth Score
75
CB Rank
42831
Heat Score
37
EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
Founded
obfuscation
PrivateSeries B Paris, Ile-de-France, France11-50 www.eg427.com
Biotechnology
Genetics
Therapeutics
Overview

EG 427
Total Funding
obfuscation
Growth Score
75
Heat Score
37

Total Funding
obfuscation
obfuscation
Series B raised
obfuscation
Growth Score75
-15 pts
in past quarter
Heat Score 37
-10 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About EG 427

CB Rank
42831
EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
Founded
obfuscation
PrivateSeries B Paris, Ile-de-France, France11-50 www.eg427.com
Biotechnology
Genetics
Therapeutics

Funding Rounds

Series B
OBF
in
obfuscation
Series A
OBF
in
obfuscation
Series A
OBF
in
obfuscation

Key People

Details

Operating Status Active
Company Type For Profit
Founders  Alberto Epstein, François Giuliano, Philippe Chambon
About the Company
EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
Predictions & Insights

Growth Insight

See this Growth Insight
EG 427 is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Key Employee Changes

Products & Services

HERMES Platform
A gene therapy platform using non-replicative herpes simplex virus type 1 (nrHSV-1) vectors for targeted gene delivery in neurology.
EG110A
A non-replicative herpes vector-based gene therapy for treating neurogenic bladder.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series B - EG 427 Logo
Series B - EG 427
3
obfuscation
Andera Partners, BpifranceSeries B
obfuscation
Series B - EG 427 Logo
Series B - EG 427
3
obfuscation
Andera Partners, BpifranceSeries B
obfuscation
Series B - EG 427 Logo
Series B - EG 427
3
obfuscation
Andera Partners, BpifranceSeries B
obfuscation
Series B - EG 427 Logo
Series B - EG 427
3
obfuscation
Andera Partners, BpifranceSeries B
obfuscation
Series B - EG 427 Logo
Series B - EG 427
3
obfuscation
Andera Partners, BpifranceSeries B

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series B - EG 427 Logo
Series B - EG 427
3
obfuscation
Andera Partners, BpifranceSeries B
obfuscation
Series B - EG 427 Logo
Series B - EG 427
3
obfuscation
Andera Partners, BpifranceSeries B
obfuscation
Series B - EG 427 Logo
Series B - EG 427
3
obfuscation
Andera Partners, BpifranceSeries B
obfuscation
Series B - EG 427 Logo
Series B - EG 427
3
obfuscation
Andera Partners, BpifranceSeries B
obfuscation
Series B - EG 427 Logo
Series B - EG 427
3
obfuscation
Andera Partners, BpifranceSeries B

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Bpifrance Logo
Bpifrance
Yes
Series B - EG 427 Logo
Series B - EG 427
Benoit Barteau
Bpifrance Logo
Bpifrance
Yes
Series B - EG 427 Logo
Series B - EG 427
Benoit Barteau
Bpifrance Logo
Bpifrance
Yes
Series B - EG 427 Logo
Series B - EG 427
Benoit Barteau
Bpifrance Logo
Bpifrance
Yes
Series B - EG 427 Logo
Series B - EG 427
Benoit Barteau
Bpifrance Logo
Bpifrance
Yes
Series B - EG 427 Logo
Series B - EG 427
Benoit Barteau
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 6 Board Members and Advisors 1

Employee Profiles

Board Members and Advisors

News

News and Press

News•Feb 24, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jan 6, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jan 6, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 2, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

395
-1.99%
 in past month

IT Spend

$53.7KThis year, EG 427 is projected to spend $53.7K on IT, according to Aberdeen.

Active Website Tech Count

17EG 427 is actively using 17 technologies for its website, according to BuiltWith. These include Euro, WordPress, and  Wordpress Plugins.

Total IP

6The intellectual property of EG 427 includes 6 registered patents primarily in the 'Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation Or Genetic Engineering' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is EG 427's headquarters? EG 427 is located in Paris, Ile-de-France, France.Who invested in EG 427? EG 427 has 5 investors including Bpifrance and  SCI Ventures.When was the last funding round for EG 427? EG 427 closed its last funding round on
obfuscation
from a Series B round.Who are EG 427's competitors? Alternatives and possible competitors to EG 427 may include Forge Biologics, Asklepios BioPharmaceutical, and  PacBio.How much funding has EG 427 raised to date? EG 427 has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(55a1db1 1)
|